Physicians' Academy for Cardiovascular Education

ACC.22

PACE-CME.org reports news from the American College of Cardiology (ACC) Scientific Sessions 2022.

Long-term efficacy and safety of radiofrequency renal denervation

5' education - Apr. 20, 2022 - Felix Mahfoud, MD

Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

3' education - Apr. 20, 2022 - Megan Coylewright, MD

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD

Novel form of CV research with dietary education in the grocery store

3' education - Apr. 13, 2022 - Prof. Eileen Handberg, PhD

EHR-based intervention improves quality care for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD

A first clinical trial testing the use of an H₂S donor after heart attack

5' education - Apr. 12, 2022 - Marie-Sophie de Koning, MD

Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

5' education - Apr. 11, 2022 - Florian Rader, MD

Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies

3' education - Apr. 6, 2022 - Brian Bergmark, MD

PCSK9i reduces plaque burden in coronary arteries

3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Reduction of bleeding with tranexamic acid after noncardiac surgery

3' education - Apr. 5, 2022 - Edward Fry, MD

Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

3' education - Apr. 4, 2022 - Maya Guglin, MD, PhD

Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

3' education - Apr. 4, 2022 - Prof. Javed Butler, MD

Updates in the new AHA/ACC/HFSA heart failure guideline

3' education - Apr. 3, 2022 - Prof. Paul Heidenreich, MD

Treatment of chronic hypertension reduces adverse pregnancy outcomes

3' education - Apr. 3, 2022 - Prof. Alan Tita, MD, PhD

Impact of new first-in-class medical therapy in obstructive HCM

3' education - Apr. 3, 2022 - Joseph Cleveland, MD

Study on effects of low-sodium diet on clinical events in HF

3' education - Apr. 2, 2022 - Prof. Justin Ezekowitz

Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM

3' education - Apr. 2, 2022 - Prof. Milind Desai, MD

Long-term efficacy and safety of radiofrequency renal denervation

5' education - Apr. 20, 2022 - Felix Mahfoud, MD
The long-term follow-up of the SPYRAL HTN-ON MED trial showed that radiofrequency renal denervation is associated with clinically meaningful BP reductions up to 36 months, without safety issues, in patients with uncontrolled hypertension on antihypertensive medications.

ACC 2022 The long-term follow-up of the SPYRAL HTN-ON MED trial showed that radiofrequency renal denervation is associated with clinically meaningful BP reductions up to 36 months, without safety issues, in patients with uncontrolled hypertension on antihypertensive medications.

Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves

3' education - Apr. 20, 2022 - Megan Coylewright, MD
An analysis showed that transcatheter aortic valves were less likely to have hemodynamic valve deterioration over a 5-year period compared to surgical valves. “This is potentially practice changing” said Coylewright.

ACC 2022 An analysis showed that transcatheter aortic valves were less likely to have hemodynamic valve deterioration over a 5-year period compared to surgical valves. “This is potentially practice changing” said Coylewright.

Bempedoic acid lowers LDL-c safely in subgroups of patients

News - Apr. 19, 2022

ACC 2022 Two analyses using data of four phase 3 trials show that treatment with bempedoic acid lowers LDL-c in patients with renal impairment and in patients with hypertension. In addition, the analyses showed that bempedoic acid was generally well tolerated in these patients.

Sustained LDL-c lowering with PCSK9 siRNA in patients with prior MI

News - Apr. 19, 2022

ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.

A positive view on a negative trial with DOAC after TAVR

3' education - Apr. 19, 2022 - Megan Coylewright, MD
Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.

ACC 2022 Megan Coylewright gives her view on the results of the ADAPT-TAVR trial which investigated whether edoxaban, compared to DAPT can reduce leaflet thrombosis, cerebral thromboembolism and neurological/neurocognitive dysfunction after TAVR.

Novel form of CV research with dietary education in the grocery store

3' education - Apr. 13, 2022 - Prof. Eileen Handberg, PhD
Prof. Handberg shares and interprets the findings from the SuperWIN study.

ACC 2022 Prof. Handberg shares and interprets the findings from the SuperWIN study. "We have the ability with this type of intervention to really impact multiple generations", she said.

EHR-based intervention improves quality care for patients with HF

3' education - Apr. 13, 2022 - Tariq Ahmad, MD
Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

ACC 2022 Tariq Ahmad discusses the results of the PROMPT-HF study that tested the hypothesis that targeted electronic health record (EHR) alerts recommending guideline-directed medical therapy (GDMT) for HFrEF would lead to higher rates of GDMT prescription compared with usual care.

Electronic health record alert improves guideline-directed therapy prescription for HFrEF

News - Apr. 12, 2022

ACC 2022 A randomized trial showed that a EHR-based alert led to higher rates of guideline-directed medical therapy (GDMT) prescription for patients with HFrEF compared with usual care.

A first clinical trial testing the use of an H₂S donor after heart attack

5' education - Apr. 12, 2022 - Marie-Sophie de Koning, MD
Does sodium thiosulfate reduces infarct size in patients after STEMI? Marie-Sophie de Koning presents the findings of the GIPS-IV trial.

ACC 2022 Does sodium thiosulfate reduces infarct size in patients after STEMI? Marie-Sophie de Koning presents the findings of the GIPS-IV trial.

H₂S donor does not reduce infarct size after STEMI

News - Apr. 12, 2022

ACC 2022 There was no reduction in infarct size after 4 months in STEMI patients treated with sodium thiosulfate compared with patients in the placebo group, in the GIPS-IV trial.

Factor XIa inhibitor lowers bleeding rate compared with NOAC in AF patients

News - Apr. 11, 2022

ACC 2022 The factor XIa inhibitor asundexian lowers bleeding rate compared with apixaban in patients with AF in the phase 2 PACIFIC-AF trial.

Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM

5' education - Apr. 11, 2022 - Florian Rader, MD
Florian Rader presents interim results of MAVA-LTE, a long-term extension study of EXPLORER-HCM with mavacamten in hypertrophic cardiomyopathy (HCM).

ACC 2022 Florian Rader presents interim results of MAVA-LTE, a long-term extension study of EXPLORER-HCM with mavacamten in hypertrophic cardiomyopathy (HCM).

ACC.22